Nicholas C. Turner

Research interests

Publications

• Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

  New England Journal of Medicine · 2023 · 10.1056/nejmoa2214131

• ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.05.520

• ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

  Annals of Oncology · 2021 · 10.1016/j.annonc.2021.09.019

• Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(20)30754-3

• Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30444-7

• Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future

  The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)30165-3

• Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.18.00925

• Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer

  JAMA Oncology · 2019 · https://doi.org/10.1001/jamaoncol.2019.1838

• Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2017.76.8671

• Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1810527

• The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial

  Cancer Discovery · 2018 · https://doi.org/10.1158/2159-8290.cd-18-0264

• Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

  Nature Communications · 2018 · https://doi.org/10.1038/s41467-018-03215-x

• Advances and challenges in targeting FGFR signalling in cancer

  Nature reviews. Cancer · 2017 · https://doi.org/10.1038/nrc.2017.8

• Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(15)00613-0

• Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

  Cancer Research · 2016 · https://doi.org/10.1158/0008-5472.can-15-0728

• Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2016.67.3061

• High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial

  Cancer Discovery · 2016 · https://doi.org/10.1158/2159-8290.cd-15-1246

• Treating cancer with selective CDK4/6 inhibitors

  Nature Reviews Clinical Oncology · 2016 · https://doi.org/10.1038/nrclinonc.2016.26

• Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

  Science Translational Medicine · 2015 · https://doi.org/10.1126/scitranslmed.aac7551

• Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1505270

• Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

  Science Translational Medicine · 2015 · 10.1126/scitranslmed.aab0021

• The history and future of targeting cyclin-dependent kinases in cancer therapy

  Nature Reviews Drug Discovery · 2015 · https://doi.org/10.1038/nrd4504

• Genetic heterogeneity and cancer drug resistance

  The Lancet Oncology · 2012 · https://doi.org/10.1016/s1470-2045(11)70335-7

• FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer

  Cancer Research · 2010 · 10.1158/0008-5472.can-09-3746

• Fibroblast growth factor signalling: from development to cancer

  Nature reviews. Cancer · 2010 · https://doi.org/10.1038/nrc2780

• Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

  Cancer Research · 2006 · https://doi.org/10.1158/0008-5472.can-06-0140

• BRCA1 dysfunction in sporadic basal-like breast cancer

  Oncogene · 2006 · https://doi.org/10.1038/sj.onc.1210014

• Basal-like breast cancer and the BRCA1 phenotype

  Oncogene · 2006 · https://doi.org/10.1038/sj.onc.1209876

• Hallmarks of 'BRCAness' in sporadic cancers

  Nature reviews. Cancer · 2004 · https://doi.org/10.1038/nrc1457

Current projects

No projects listed.